Lynnette Fernandez-Cuesta and Matthieu Foll presented the RCG research advances on the molecular characterisation of lung neuroendocrine tumor during the European Association of Nuclear Medicine Multidisciplinary Days (Multidisciplinary Days – EANM’22), in the symposium entitled “Imaging, Targeted Radionuclide Therapy of Lung NETs – Current and Future Directions”. This is part of our ongoing effort to translate our molecular discoveries into clinical practice thanks to our new collaboration with Prof. David Taieb (APHM, Marseille, France).